NEWS
Cyclo Therapeutics Presents Encouraging Preliminary Safety Data from Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (NPC1)
Cyclo Therapeutics (Nasdaq: CYTH) presented encouraging preliminary safety data from its ongoing pivotal Phase 3 study (TransportNPC™) and substudy evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1) at the SSIEM Annual Symposium 2024. The TransportNPC™ study, with 104 enrolled patients, is the most comprehensive controlled pivotal study for NPC1. Key highlights include:
1. Topline data from the 48-week interim analysis expected in H1 2025
2. Trappsol® Cyclo™ demonstrated to be well-tolerated with a consistent safety profile
3. 625 Adverse Events reported, 80% Grade 1 (mild)
4. No patients withdrew due to safety concerns
5. Substudy completed enrollment with ten patients under 3 years old
1. Topline data from the 48-week interim analysis expected in H1 2025
2. Trappsol® Cyclo™ demonstrated to be well-tolerated with a consistent safety profile
3. 625 Adverse Events reported, 80% Grade 1 (mild)
4. No patients withdrew due to safety concerns
5. Substudy completed enrollment with ten patients under 3 years old
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1778Followers
98Following
14KVisitors
Follow